toxylact: a02bc pantoprazole

The first professional lActological database in the word

Pantoprazole (ATC A02BC02) is a direct-acting proton pump inhibitor used for acid‑related gastrointestinal disorders and is considered compatible with breastfeeding, with minimal infant exposure through breast milk.file+4

Pharmacological overview

Pantoprazole is a substituted benzimidazole that suppresses gastric acid secretion by specifically blocking the gastric hydrogen‑potassium ATPase (proton pump) in parietal cells.europa+3
It belongs to the ATC group A02BC “Proton pump inhibitors”, with a defined daily dose of 40 mg for oral treatment of gastro‑oesophageal reflux disease.atcddd.fhi

Pantoprazole is used in erosive gastritis, symptomatic gastro‑oesophageal reflux disease, peptic ulcer disease, NSAID‑associated ulceration, Helicobacter pylori eradication regimens, stress ulcer prophylaxis, and hypersecretory conditions including Zollinger–Ellison syndrome.drugsporphyria+3
Therapy is usually limited to several weeks in common indications, although higher or prolonged dosing can be required in rare hypersecretory states.drugbank+2

Toxicology and general safety

Pantoprazole is generally well tolerated; common adverse reactions include headache, dizziness, gastrointestinal symptoms (nausea, vomiting, flatulence, diarrhoea), and cutaneous or systemic hypersensitivity reactions.pubmed.ncbi.nlm.nih+2
Rare but clinically relevant risks include Clostridioides difficile‑associated diarrhoea, hypomagnesaemia, vitamin B12 deficiency, acute interstitial nephritis, bone fractures with long‑term use, and potential lymphoid proliferations such as MALT lymphoma.lakemedelsverket+3

Pantoprazole is metabolised hepatically via cytochrome P450, with interactions reported with drugs such as warfarin and some antiretrovirals, and with substances whose absorption depends on gastric acidity (e.g. ketoconazole, iron salts).accessdata.fda+2
The drug has a relatively short plasma half‑life (~1 hour) but a prolonged antisecretory effect lasting several days after discontinuation due to irreversible pump binding.file+2

Pregnancy risk profile

Regulatory data classify pantoprazole as FDA pregnancy category B, based on animal studies not demonstrating fetal harm and limited human exposure data.facebook+2
Clinical guidance often prefers omeprazole in pregnancy because more human data are available, but pantoprazole may be used when benefits outweigh potential risks in women with significant acid‑related disease.pubmed.ncbi.nlm.nih+2

Recent pharmacovigilance analyses have identified disproportionality signals for pregnancy‑related adverse events (e.g. premature labour, low birth weight, morning sickness) with proton pump inhibitors, including pantoprazole, although causality remains uncertain and signals may be drug‑specific rather than class‑wide.pubmed.ncbi.nlm.nih
Given these data, cautious use in pregnancy is recommended, with careful individual risk–benefit assessment and preference for the lowest effective dose and shortest duration.nhs+1

Lactation pharmacokinetics and infant exposure

Pantoprazole has a molecular weight of about 432–434 Da and is excreted into human milk in low concentrations.droracle+2
After a 40 mg maternal oral dose, reported milk levels were approximately 0.036 mg/L at 2 hours and 0.024 mg/L at 4 hours, with a maternal plasma peak around 1.65 mg/L and a milk‑to‑plasma ratio of about 0.02.droracle+1

Using these measurements, the estimated relative infant dose via breastfeeding is below 0.14% of the weight‑adjusted maternal dose, far under the commonly accepted 10% safety threshold.sps+2
Pantoprazole becomes undetectable in breast milk by 6–24 hours post‑dose, and available case data report no adverse effects in the breastfed infant.sps+1

Pantoprazole is highly unstable at gastric pH and is degraded in the infant’s stomach; therefore, systemic exposure in the breastfeeding infant is expected to be negligible.file+1
Specialist sources consider all PPIs usable in breastfeeding, with omeprazole and pantoprazole preferred because they pass into milk in very small amounts and have supportive clinical experience.nhs+1

Toxico‑lactation risk categorization and practical recommendations

Based on the very low relative infant dose, rapid disappearance from milk, and degradation in the infant gastrointestinal tract, pantoprazole is classified in a low‑risk toxico‑lactation category compatible with breastfeeding (category I in the Toxylact system).droracle+2
Breastfeeding can generally continue without interruption in mothers treated with standard doses of pantoprazole for common acid‑related conditions.nhs+2

Practical recommendations include using the lowest effective dose, monitoring the infant for non‑specific symptoms (feeding changes, gastrointestinal upset, irritability) as with any maternal medication, and considering dose timing (e.g. administering after a major feed) in very young or medically fragile infants.sps+2
In mothers with additional risk factors (severe hepatic disease, long‑term high‑dose therapy, polypharmacy), a more detailed individual risk assessment and periodic review of ongoing necessity are advisable.drugbank+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.